Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
KRAS wild-type pancreatic ductal adenocarcinoma
What changed

KRAS wild-type pancreatic ductal adenocarcinoma

What changed: KRAS wild-type pancreatic ductal adenocarcinoma

Cancer page →

Every dated change on the records linked to KRAS wild-type pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Trial result2Milestone6This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-18This recordKRAS wild-type pancreatic ductal adenocarcinoma
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 1

2025Trial resultA Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) reported
Objective response 30 percent across 158 evaluable NRG1 fusion-positive cancers, 42 percent (15 of 36) in pancreatic cancer; median duration of response 11.

2024 · 1

2024MilestoneZenocutuzumab
Zenocutuzumab approved for NRG1 fusion-positive pancreatic cancer
A milestone in how this cancer is treated.

2023 · 2

2023Trial resultNOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)
NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer) reported
Overall survival improved with nimotuzumab plus gemcitabine in KRAS wild-type disease.
2023MilestoneNOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)
NOTABLE: nimotuzumab plus gemcitabine lengthens survival in KRAS wild-type pancreatic cancer
A milestone in how this cancer is treated.

2022 · 1

2022MilestoneDabrafenib + trametinib
Dabrafenib plus trametinib approved for BRAF V600E solid tumours regardless of site
A milestone in how this cancer is treated.

2018 · 2

2018MilestoneLarotrectinib
Larotrectinib approved for NTRK fusion-positive solid tumours, pancreatic cancer included
A milestone in how this cancer is treated.
2018MilestoneGene fusion
NRG1 fusions described as a recurrent driver of KRAS wild-type pancreatic cancer
A milestone in how this cancer is treated.

2015 · 1

2015MilestoneComprehensive genomic profiling
Sequencing studies show that KRAS wild-type pancreatic cancers are enriched for alternative drivers
A milestone in how this cancer is treated.